GlaxoSmithKline reported 479.3B in Gross Profit on Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Alcon AG ALC:SW 1.19B 22.42M
Amgen AMGN:US $ 5084M 407M
Artemis Alpha ATS:LN -2637000000 1.64B
AstraZeneca AZN:LN 728.3B 34.55B
Bayer BAYN:GR 7.14B 2.32B
Biogen BIIB:US $ 2105.1M 327.2M
Bristol Myers Squibb BMY:US $ 9210M 33M
Eli Lilly And LLY:US $ 5057.5M 680.4M
Fresenius FRE:GR € 2678M 120M
Fresenius Medical Care FME:GR € 1346M 87.9M
Galapagos GLPG:NA 144.93M 3.82M
Gilead Sciences GILD:US $ 4818M 348M
GlaxoSmithKline GSK:LN 479.3B 29.3B
Glaxosmithkline GSK:US $ 4793M 1342M
Hikma Pharmaceutical HIK:LN 51.17B 538.95M
Lonza Group LONN:SW 1.2B 129M
Merck MRK:GR € 3459M 248M
Merk MRK:US $ 10895M 328M
Novartis NOVN:VX 9.34B 277M
Orion ORNBV:FH 173.5M 9M
Pfizer PFE:US $ 19071M 3420M
Philips PHIA:NA € 1732M 221M
Recordati REC:IM 320.71M 16.8M
Regeneron Pharmaceuticals REGN:US $ 2560.1M 0.1M